@inproceedings{inproceedings, title  = {{Risk factors for developing osteonecrosis of the jaw (ONJ) in patients receiving denosumab or zoledronic acid for bone metastases: Results from three phase 3 trials}},

 url = {{}},

 year = {{2013}},

 month = {{9}},

 author = {{Brown J and Saad F and Stopeck A and Fizazi K and Henry D and Diel I and De Boer R and Wang H and Braun A}},

 volume = {{49}},

 journal = {{EUROPEAN JOURNAL OF CANCER}},

 pages = {{S268-S269}},

 note = {{Accessed on 2024/12/27}}}